Combination CDC-like kinase inhibition (CLK)/Dual-specificity tyrosine-regulated kinase (DYRK) and taxane therapy in CTNNB1-mutated endometrial cancer.
Corr BR, Moroney MR, Woodruff E, Watson ZL, Jordan KR, Danhorn T, Bailey C, Wolsky RJ, Bitler BG. Combination CDC-like kinase inhibition (CLK)/Dual-specificity tyrosine-regulated kinase (DYRK) and taxane therapy in CTNNB1-mutated endometrial cancer. bioRxiv. 2023 Apr 06.